• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Eli Lilly's Charts Look a Bit Frail

LLY is looking shaky, despite fundamental improvements from its weight-loss drug tirzepatide.
By BRUCE KAMICH
May 02, 2022 | 03:08 PM EDT
Stocks quotes in this article: LLY

Shares of drugmaker Eli Lilly  (LLY)  got a price target bump by Mizuho on the strength of weight-loss drug tirzepatide. I need to lose about 15 pounds, but I am working on it without taking another drug. Let's check out the charts and indicators.  

 
In this daily bar chart of LLY, below, we can see a weakening picture. Prices are pulling back after a short-term bounce, following a deeper April correction. LLY is getting close to a test of the rising 50-day moving average line. The rising 200-day moving average line intersects down around $260 and it could be tested in the weeks ahead. The last test of the 200-day line was in February. The On-Balance-Volume (OBV) line has moved sideways since August and has failed to confirm the price gains. The Moving Average Convergence Divergence (MACD) oscillator is pointed down towards the zero-line. 
 
 
In this weekly Japanese candlestick chart of LLY, below, we can see that prices tripled in the past three years. LLY is pulling back but still stands above the rising 40-week moving average line. The weekly OBV line is different from the daily line. Here the line shows a bullish rise for the past three years. The MACD oscillator is above the zero-line, but narrowing toward a potential bearish crossover. 
 
 
 
In this daily Point and Figure chart of LLY, below, we can see a potential upside price target in the $475 area. A trade at $276 could begin to weaken the picture. 
 
 
In this weekly Point and Figure chart of LLY, below, we can see the same $475 target as the daily chart. 
 
 
Bottom line strategy: In our April 28 review of LLY, we recommended that, "In the short run the better-than-expected numbers from Lilly may keep the stock buoyant, but the divergences noted above tell me to at least be cautious or even defensive going forward." Traders should be more cautious on LLY now. Take profits and raise stops on any remaining longs to $275 from $271.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Technical Analysis | Trading | Pharmaceuticals | Analyst Actions

More from Investing

Paychex's Charts Indicate It May Not Pay to Hold Its Shares Right Now

Bruce Kamich
Jun 29, 2022 8:36 AM EDT

The technical indicators of the provider of human resources and payroll services are not favorable at present.

Down Market, Negative Growth, Recession Talk, AMD, Trading AeroVironment

Stephen Guilfoyle
Jun 29, 2022 7:53 AM EDT

All of the talk around recession that had abated, at least for a day, returned with a vengeance, supported by a Cathie Wood interview.

A Market for Sitting on the Sidelines

James "Rev Shark" DePorre
Jun 29, 2022 7:52 AM EDT

There may be some short-term trades and perhaps a few buying opportunities of unfairly hit stocks, but it just isn't the time to be active.

Griffon Corp.: Under-loved, Under-followed, Ready to Rumble

Paul Price
Jun 29, 2022 7:00 AM EDT

The maker of building products appears significantly undervalued based on its results and earnings prospects; here's how to play it.

Naspers to Unlock Its Own Value By Selling Down $129B Tencent Stake

Alex Frew McMillan
Jun 29, 2022 6:32 AM EDT

Naspers and its investment-holding company Prosus will sell down their Tencent stake and buy their own shares, with both companies trading at big discounts to NAV.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login